MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Inicio・Lista de Acciones・Veracyte Inc

Veracyte Inc

Cerrado

SectorSalud

41.99 -3.58

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

41.94

Máximo

42.76

Métricas clave
By Trading Economics
Ingresos	12M 19M
Ventas	1.7M 132M
P/B Media del Sector	111.872 87.826
Margen de beneficio	14.512
Empleados	824
EBITDA	4.4M 24M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+5.92% upside

Dividendos
By Dow Jones
Próximas Ganancias	23 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	581M 3.4B
Apertura anterior	45.57
Cierre anterior	41.99

Noticias sobre sentimiento de mercado

By Acuity

89%

11%

358 / 370 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

30.5 / 31.38 Soporte y Resistencia

Veracyte Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 ene 2026, 22:18 UTC

Charlas de Mercado

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 ene 2026, 21:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

9 ene 2026, 21:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

9 ene 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 ene 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

9 ene 2026, 21:43 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 ene 2026, 20:39 UTC

Charlas de Mercado

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 ene 2026, 20:38 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 ene 2026, 20:36 UTC

Adquisiciones, fusiones, absorciones

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 ene 2026, 20:30 UTC

Charlas de Mercado

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 ene 2026, 20:15 UTC

Charlas de Mercado

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 ene 2026, 20:07 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

9 ene 2026, 20:07 UTC

Charlas de Mercado

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 ene 2026, 19:58 UTC

Adquisiciones, fusiones, absorciones

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 ene 2026, 19:42 UTC

Charlas de Mercado

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 ene 2026, 19:38 UTC

Adquisiciones, fusiones, absorciones

Wolters Kluwer Acquires StandardFusion >WTKWY

9 ene 2026, 19:31 UTC

Ganancias

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 ene 2026, 19:28 UTC

Ganancias

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 ene 2026, 18:30 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 ene 2026, 18:23 UTC

Charlas de Mercado

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 ene 2026, 17:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

9 ene 2026, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 ene 2026, 17:19 UTC

Charlas de Mercado

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9 ene 2026, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

9 ene 2026, 17:07 UTC

Charlas de Mercado

McDonald's Promotions Appear Successful -- Market Talk

9 ene 2026, 17:06 UTC

Charlas de Mercado

Oil Futures on Track for Weekly Gains -- Market Talk

9 ene 2026, 17:05 UTC

Ganancias

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9 ene 2026, 16:57 UTC

Charlas de Mercado

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9 ene 2026, 16:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 ene 2026, 16:46 UTC

Charlas de Mercado

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Comparación entre iguales

Cambio de precio

Veracyte Inc Esperado

Precio Objetivo

By TipRanks

5.92% repunte

Estimación a 12 meses

Media 46.14 USD 5.92%

Máximo 50 USD

Mínimo 43 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Veracyte Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Veracyte Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

30.5 / 31.38Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Sentimiento

By Acuity

358 / 370 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.